| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 02/08/2006 | EP1623710A1 Receptor antagonist |
| 02/08/2006 | EP1623704A1 Therapeutic agent |
| 02/08/2006 | EP1237904B1 14,15-beta-methylene substituted androgens |
| 02/08/2006 | EP1235776B1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 02/08/2006 | CN1732002A Derivatives of aryl-quinazoline/aryl-2amino-phenyl methanone which promote the release of parathyroid hormone |
| 02/08/2006 | CN1240718C Aggregates of human insulin derivatives |
| 02/08/2006 | CN1240387C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 02/08/2006 | CN1240375C Preparation of low dosage medicinal composition with uniform distribution and effect |
| 02/07/2006 | US6995150 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol |
| 02/07/2006 | US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 02/07/2006 | CA2360308C Glucocorticoid receptor modulators |
| 02/02/2006 | WO2006010560A2 Physiologically active composition |
| 02/02/2006 | US20060025432 N-[2-[(3-Chloro-2-fluorobenzyl)thio]-6-[(2-hydroxy-1-methylethyl)amino]-4-pyrimidinyl]- 4-morpholinesulfonamide; asthma, antiallergens; rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis |
| 02/02/2006 | US20060025427 Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| 02/02/2006 | US20060025423 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/02/2006 | US20060025418 Methods of making and using N-desmethylzopiclone |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060024772 Parathyroid hormone antibodies and related methods |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/02/2006 | CA2574894A1 Physiologically active composition |
| 02/01/2006 | EP1621549A2 Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments |
| 02/01/2006 | EP1621199A1 Remedies for diseases to be applied to eye |
| 02/01/2006 | EP1620392A2 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 02/01/2006 | EP1620058A2 Composition for improving cognition and memory |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1425281B1 Tricyclic CRF receptor antagonists |
| 02/01/2006 | EP1235812B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 02/01/2006 | EP1194409B1 Pyrazolidinol compounds |
| 02/01/2006 | EP1169336B1 Ent-steroids as selectively active estrogens |
| 02/01/2006 | CN1729185A Nobel compounds having selective inhibiting effect at GSK3 |
| 02/01/2006 | CN1729176A Tetrahydroquinoline derivatives and their use as FSH receptor modulators |
| 02/01/2006 | CN1729175A Tetrahydroquinoline derivatives |
| 02/01/2006 | CN1729002A Exemestane as chemopreventing agent |
| 02/01/2006 | CN1728989A Use of extracts containing phytoestrogen selectively modulating estrogen-receptor-beta. |
| 02/01/2006 | CN1239167C Medicines for treating thyroma and hydatoncus |
| 02/01/2006 | CN1239160C Hormone replacement therapy |
| 02/01/2006 | CN1239153C Transdermal therapeutic system based on polyacrylate-contact-bonding adhesives without functional groups |
| 01/31/2006 | US6992075 dehydrogenating estrogenic salts by heating in high humidity to produce conjugated estrogen salts; 14-hydroxy (or hydroperoxy)- Delta 8,9-Dehydroestrone Sodium Sulfate; side effect reduction; hormone replacement therapy |
| 01/31/2006 | US6992074 2-Ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/31/2006 | US6992067 Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use |
| 01/31/2006 | US6992065 Sustained release formulations |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006008316A2 Selective inhibitors of human corticosteroid syntheses |
| 01/26/2006 | US20060020046 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| 01/26/2006 | US20060020002 (3a alpha ,4 alpha ,7 alpha ,7a alpha )-Octahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (2); steroid mimic; competitive inhibitors of intercellular ligand binding reactions involving CAMs and Leukointegrins; anticarcinogenic agent; autoimmune diseases |
| 01/26/2006 | US20060019996 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 01/26/2006 | US20060019945 Granzyme b inhibitors |
| 01/26/2006 | US20060019897 Anti-angiogenic polypeptides |
| 01/25/2006 | EP1619203A1 Galectin 9-inducing factor |
| 01/25/2006 | EP1617856A2 Somatostatin-dopamine chimeric analogs |
| 01/25/2006 | EP1235825B1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 01/25/2006 | EP1135127B1 New pharmaceutical composition and the process for its preparation |
| 01/25/2006 | CN1726210A Novel compounds having selective inhibiting effect at GSK3 |
| 01/25/2006 | CN1726023A Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| 01/25/2006 | CN1726022A Pregabalin derivatives for the treatment of fibromyalgia and other disorders and its derivitive |
| 01/25/2006 | CN1726014A Novel dry powder inhalation system for transpulmonary administration |
| 01/25/2006 | CN1724066A Controlled release composition and method of producing the same |
| 01/25/2006 | CN1724036A Medicine for improving internal secreting melatonin, and application of its related herb medicine |
| 01/25/2006 | CN1238341C 1 Alpha-hydroxy-25-ene-vitamin D, analogs and use thereof |
| 01/24/2006 | US6989402 Thyroid receptor ligands and method II |
| 01/24/2006 | US6989385 Pyrazole compounds useful as protein kinase inhibitors |
| 01/24/2006 | CA2368431C Melanocortin receptor ligands |
| 01/19/2006 | WO2006005759A2 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | WO2006005726A2 Heterocyclic compounds |
| 01/19/2006 | WO2006005667A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 01/19/2006 | US20060014823 Method for the purification of liponic acid |
| 01/19/2006 | US20060014787 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/19/2006 | US20060014755 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/19/2006 | US20060014750 Pharmaceutical compositions for the treatment of CNS and other disorders |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | CA2573456A1 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 01/19/2006 | CA2571739A1 A composition comprising a pharmacologically active agent coupled to a target cell specific component, and a saponin |
| 01/19/2006 | CA2561841A1 Methods for suppressing neovascularization using ephrinb2 |
| 01/18/2006 | EP1616565A1 Composition for relieving unpleasant symptoms accompanying change in protesterone |
| 01/18/2006 | EP1616182A2 Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 |
| 01/18/2006 | EP1615944A2 Antiandrogens with marginal agonist activity and methods of use |
| 01/18/2006 | EP1615932A2 Podophhyllotoxin derivatives as igf-1r inhibitors |
| 01/18/2006 | EP1615650A1 Phosphate derivatives of pharmaceutical products |
| 01/18/2006 | EP1615647A2 Pharmaceutical use of fused 1,2,4-triazoles |
| 01/18/2006 | EP1412338B1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 01/18/2006 | EP1212335B1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols |
| 01/18/2006 | CN1723059A Insulin receptor activators for the treatment of human body metabolic disorder resulting from treatment of HIV infection with HIV protease inhibitors |
| 01/18/2006 | CN1723052A Enhanced parmacokinetic profile of hydrophobic dopamine agonists administered to the dermis |
| 01/18/2006 | CN1720991A Degraded agonist antibody |
| 01/18/2006 | CN1720924A Application of montmorillonite in pharmacy |
| 01/18/2006 | CN1237061C Chemokine receptor binding heterocyclic compounds |
| 01/18/2006 | CN1236831C Compositions for protein delivery via the pulmonary route |
| 01/17/2006 | US6987098 Health supplement |
| 01/17/2006 | US6987088 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 01/17/2006 | US6987005 Where the human SNORF33 receptor has the amino acid sequence SEQ ID NO: 6; encoded by ATCC deposited plasmids; activated by either tyramine, tryptamine, or beta -phenyl-ethylamine; vectors; cells; membranes; nervous system disorders |
| 01/17/2006 | US6986346 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 01/12/2006 | US20060009527 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009526 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009494 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 01/12/2006 | US20060009436 11 beta -Fluoro-7 alpha -{5-[methyl(7,7,8,8,9,9,9-heptafluorononyl)amino]pentyl}-17 alpha -methylestra-1,3,5(10)-triene-3,17 beta -diol N-oxide; antiestrogen compound whose metabolism can be controlled; alveolar macrophages do not build up; oral administration |
| 01/12/2006 | DE102004030880A1 Methode zur Behandlung von Diabetes Method for the treatment of diabetes |
| 01/11/2006 | EP1614675A2 Amino acids with affinity for the alpha-2-delta protein |
| 01/11/2006 | EP1614418A1 use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia |